{
  "drugs": [
    {
      "Generic Name": "Paracetamol",
      "Brand Names": "Dolo 650, Calpol",
      "Drug Class": "Analgesic, Antipyretic",
      "Mechanism of Action": "Inhibits prostaglandin synthesis by blocking COX enzymes in the CNS",
      "Indications": "Fever, mild to moderate pain (headache, myalgia, post-vaccination fever)",
      "Dosage & Route": "500–1000 mg orally every 4–6 hours; max 4g/day",
      "Absorption": "Rapidly absorbed from GI tract; peak levels in 30–60 min",
      "Distribution": "Widely distributed; crosses placenta and BBB",
      "Metabolism": "Primarily hepatic (via glucuronidation and sulfation)",
      "Elimination": "90–100% via urine within 24 hrs",
      "Adverse Effects": "Nausea, rash, liver toxicity at high doses, hepatotoxicity in overdose",
      "Contraindications": "Severe hepatic impairment, chronic alcohol abuse",
      "Drug Interactions": "↑ bleeding risk with warfarin, ↑ liver damage with alcohol, enzyme inducers may increase toxic metabolites",
      "Monitoring Parameters": "LFTs in long-term/high-dose users",
      "Patient Counseling Points": "Avoid overdose; do not exceed 4g/day; store safely away from children",
      "Cost (₹/tab)": "₹1.5",
      "Availability (Govt/Private)": "Govt hospitals, pharmacies statewide",
      "Schedule": "H"
    },
    {
      "Generic Name": "Metformin",
      "Brand Names": "Glyciphage, Gluformin",
      "Drug Class": "Biguanide",
      "Mechanism of Action": "Decreases hepatic glucose production, increases peripheral glucose uptake, improves insulin sensitivity",
      "Indications": "Type 2 diabetes mellitus, PCOS",
      "Dosage & Route": "Initial: 500 mg once/twice daily; Max: 2000 mg/day orally",
      "Absorption": "50–60% bioavailability; peak in 2–3 hrs",
      "Distribution": "Not protein-bound; Vd ~654 L",
      "Metabolism": "Not metabolized",
      "Elimination": "Excreted unchanged in urine; t1/2 ~6 hrs",
      "Adverse Effects": "Diarrhea, nausea, metallic taste, lactic acidosis (rare)",
      "Contraindications": "eGFR <30, metabolic acidosis, severe liver disease",
      "Drug Interactions": "Contrast media (renal risk), alcohol (↑ lactic acidosis), cimetidine (↑ metformin)",
      "Monitoring Parameters": "Renal function (eGFR), B12 (long-term use)",
      "Patient Counseling Points": "Take after meals to reduce GI upset; report fatigue or breathlessness",
      "Cost (₹/tab)": "₹2",
      "Availability (Govt/Private)": "Widely available, Karunya outlets",
      "Schedule": "H"
    },
    {
      "Generic Name": "Amlodipine",
      "Brand Names": "Amlong, Stamlo",
      "Drug Class": "Dihydropyridine Calcium Channel Blocker",
      "Mechanism of Action": "Inhibits calcium influx in vascular smooth muscle → vasodilation",
      "Indications": "Hypertension, angina, vasospastic angina",
      "Dosage & Route": "5–10 mg once daily orally",
      "Absorption": "~60–70% oral bioavailability",
      "Distribution": "Highly protein-bound (~93%)",
      "Metabolism": "Hepatic metabolism via CYP3A4",
      "Elimination": "Excreted via urine; t1/2 ~30–50 hrs",
      "Adverse Effects": "Ankle edema, flushing, palpitations, fatigue",
      "Contraindications": "Severe hypotension, cardiogenic shock",
      "Drug Interactions": "CYP3A4 inhibitors (↑ levels), beta-blockers (additive bradycardia)",
      "Monitoring Parameters": "BP, HR, signs of fluid retention",
      "Patient Counseling Points": "Take at same time daily; do not stop abruptly; avoid grapefruit juice",
      "Cost (₹/tab)": "₹4",
      "Availability (Govt/Private)": "Available in private and govt setups",
      "Schedule": "H"
    },
    {
      "Generic Name": "Pantoprazole",
      "Brand Names": "Pantodac, Pan 40",
      "Drug Class": "Proton Pump Inhibitor",
      "Mechanism of Action": "Irreversibly inhibits H+/K+ ATPase in gastric parietal cells → suppresses acid",
      "Indications": "GERD, peptic ulcer disease, Zollinger-Ellison syndrome",
      "Dosage & Route": "40 mg once daily orally/IV; 20 mg for mild reflux",
      "Absorption": "Rapid absorption, delayed by food; bioavailability ~77%",
      "Distribution": "98% plasma protein-bound",
      "Metabolism": "Hepatic (CYP2C19, CYP3A4)",
      "Elimination": "Urine (~80%), feces (~20%)",
      "Adverse Effects": "Headache, diarrhea, abdominal pain, B12 deficiency (long term)",
      "Contraindications": "Hypersensitivity, caution in hepatic impairment",
      "Drug Interactions": "Clopidogrel (↓ effect), warfarin (↑ INR), ketoconazole (↓ absorption)",
      "Monitoring Parameters": "Mg, B12 (long term), gastric symptoms",
      "Patient Counseling Points": "Take 30 mins before breakfast; do not chew/crush",
      "Cost (₹/tab)": "₹4–₹6",
      "Availability (Govt/Private)": "Widely available",
      "Schedule": "H"
    },
    {
      "Generic Name": "Montelukast",
      "Brand Names": "Montek LC, Montair",
      "Drug Class": "Leukotriene receptor antagonist",
      "Mechanism of Action": "Blocks leukotriene D4 receptors in lungs → ↓ bronchoconstriction/inflammation",
      "Indications": "Allergic rhinitis, asthma prophylaxis, exercise-induced asthma",
      "Dosage & Route": "10 mg once daily at bedtime",
      "Absorption": "Rapidly absorbed; peak at 3–4 hrs",
      "Distribution": ">99% protein-bound",
      "Metabolism": "Hepatic (CYP3A4, CYP2C9)",
      "Elimination": "Feces (~80%), urine (~10%)",
      "Adverse Effects": "Headache, abdominal pain, neuropsychiatric symptoms (rare)",
      "Contraindications": "Acute asthma attack (not for rescue), phenylketonuria (some forms)",
      "Drug Interactions": "Phenobarbital (↓ effect), CYP inducers",
      "Monitoring Parameters": "Mood/behavior changes (rare), asthma symptoms",
      "Patient Counseling Points": "Take once daily, even if asymptomatic; not for acute attack",
      "Cost (₹/tab)": "₹5–₹7",
      "Availability (Govt/Private)": "Private pharmacies",
      "Schedule": "H"
    },
    {
      "Generic Name": "Amoxicillin + Clavulanic Acid",
      "Brand Names": "Augmentin, Clavam, Moxikind-CV",
      "Drug Class": "Beta-lactam antibiotic + beta-lactamase inhibitor",
      "Mechanism of Action": "Inhibits bacterial cell wall synthesis; clavulanic acid protects amoxicillin from degradation.",
      "Indications": "Respiratory, urinary, skin infections",
      "Dosage & Route": "500/125 mg TDS orally",
      "Absorption": "Well absorbed orally",
      "Distribution": "Widely distributed; crosses placenta",
      "Metabolism": "Partial hepatic metabolism",
      "Elimination": "Renal excretion",
      "Adverse Effects": "Diarrhea, rash, nausea",
      "Contraindications": "Methotrexate toxicity ↑; OCP efficacy ↓",
      "Drug Interactions": "Liver, renal function, hypersensitivity",
      "Monitoring Parameters": "Complete full course",
      "Patient Counseling Points": "₹20",
      "Cost (₹/tab)": "Both",
      "Availability (Govt/Private)": "H",
      "Schedule": ""
    },
    {
      "Generic Name": "Losartan",
      "Brand Names": "Losar, Repace",
      "Drug Class": "ARB",
      "Mechanism of Action": "Blocks angiotensin II receptor → ↓BP",
      "Indications": "Hypertension, nephropathy",
      "Dosage & Route": "50 mg OD",
      "Absorption": "Moderate oral absorption",
      "Distribution": "Protein bound",
      "Metabolism": "Hepatic (CYP2C9)",
      "Elimination": "Renal & biliary",
      "Adverse Effects": "Hyperkalemia, dizziness",
      "Contraindications": "Additive with antihypertensives",
      "Drug Interactions": "BP, K+, renal fxn",
      "Monitoring Parameters": "Avoid high-K foods",
      "Patient Counseling Points": "₹7",
      "Cost (₹/tab)": "Both",
      "Availability (Govt/Private)": "H",
      "Schedule": ""
    },
    {
      "Generic Name": "Atorvastatin",
      "Brand Names": "Lipitor, Atocor",
      "Drug Class": "Statin",
      "Mechanism of Action": "Inhibits HMG-CoA reductase → ↓cholesterol",
      "Indications": "Dyslipidemia, IHD prevention",
      "Dosage & Route": "10-20 mg OD",
      "Absorption": "Well absorbed",
      "Distribution": "High protein binding",
      "Metabolism": "Hepatic (CYP3A4)",
      "Elimination": "Biliary",
      "Adverse Effects": "Myopathy, LFT ↑",
      "Contraindications": "CYP3A4 inhibitors ↑ toxicity",
      "Drug Interactions": "LFTs, CK",
      "Monitoring Parameters": "Report muscle pain",
      "Patient Counseling Points": "₹15",
      "Cost (₹/tab)": "Both",
      "Availability (Govt/Private)": "H",
      "Schedule": ""
    },
    {
      "Generic Name": "Clopidogrel",
      "Brand Names": "Clopivas, Deplatt",
      "Drug Class": "Antiplatelet",
      "Mechanism of Action": "Inhibits ADP platelet aggregation",
      "Indications": "IHD, stroke prevention",
      "Dosage & Route": "75 mg OD",
      "Absorption": "Rapid oral",
      "Distribution": "98% protein bound",
      "Metabolism": "Hepatic",
      "Elimination": "Renal, fecal",
      "Adverse Effects": "Bleeding",
      "Contraindications": "PPI ↓ efficacy",
      "Drug Interactions": "Bleeding signs",
      "Monitoring Parameters": "Report unusual bleeding",
      "Patient Counseling Points": "₹10",
      "Cost (₹/tab)": "Both",
      "Availability (Govt/Private)": "H",
      "Schedule": ""
    },
    {
      "Generic Name": "Budesonide + Formoterol",
      "Brand Names": "Foracort, Budecort",
      "Drug Class": "ICS + LABA",
      "Mechanism of Action": "Anti-inflammatory + bronchodilation",
      "Indications": "Asthma, COPD",
      "Dosage & Route": "1-2 puffs BD",
      "Absorption": "Lung absorption",
      "Distribution": "Plasma protein bound",
      "Metabolism": "Hepatic",
      "Elimination": "Renal",
      "Adverse Effects": "Oral thrush, tremor",
      "Contraindications": "Beta-blockers ↓ effect",
      "Drug Interactions": "Symptoms, technique",
      "Monitoring Parameters": "Rinse mouth post use",
      "Patient Counseling Points": "₹300/inhaler",
      "Cost (₹/tab)": "Both",
      "Availability (Govt/Private)": "H",
      "Schedule": ""
    },
    {
      "Generic Name": "Azithromycin",
      "Brand Names": "Azithral, Zithrocin",
      "Drug Class": "Macrolide antibiotic",
      "Mechanism of Action": "Inhibits bacterial protein synthesis",
      "Indications": "RTI, skin infections",
      "Dosage & Route": "500 mg OD",
      "Absorption": "Good oral",
      "Distribution": "Tissue penetration",
      "Metabolism": "Minimal",
      "Elimination": "Biliary",
      "Adverse Effects": "GI upset, QT prolongation",
      "Contraindications": "QT prolongers ↑ risk",
      "Drug Interactions": "ECG if risk factors",
      "Monitoring Parameters": "Take on empty stomach",
      "Patient Counseling Points": "₹20",
      "Cost (₹/tab)": "Both",
      "Availability (Govt/Private)": "H",
      "Schedule": ""
    },
    {
      "Generic Name": "Cefixime",
      "Brand Names": "Zifi, Taxim-O",
      "Drug Class": "3rd gen cephalosporin",
      "Mechanism of Action": "Inhibits cell wall synthesis",
      "Indications": "RTI, UTI",
      "Dosage & Route": "200 mg BD",
      "Absorption": "40-50% oral",
      "Distribution": "Wide",
      "Metabolism": "Negligible",
      "Elimination": "Renal",
      "Adverse Effects": "GI upset",
      "Contraindications": "Warfarin ↑ effect",
      "Drug Interactions": "Renal fxn",
      "Monitoring Parameters": "Complete course",
      "Patient Counseling Points": "₹25",
      "Cost (₹/tab)": "Both",
      "Availability (Govt/Private)": "H",
      "Schedule": ""
    },
    {
      "Generic Name": "Rabeprazole",
      "Brand Names": "Acidil, Rabium",
      "Drug Class": "PPI",
      "Mechanism of Action": "Inhibits gastric acid secretion",
      "Indications": "GERD, ulcer",
      "Dosage & Route": "20 mg OD",
      "Absorption": "Rapid",
      "Distribution": "Wide",
      "Metabolism": "Hepatic",
      "Elimination": "Renal",
      "Adverse Effects": "Headache, diarrhea",
      "Contraindications": "↓ Clopidogrel efficacy",
      "Drug Interactions": "Symptoms",
      "Monitoring Parameters": "Take before meals",
      "Patient Counseling Points": "₹8",
      "Cost (₹/tab)": "Both",
      "Availability (Govt/Private)": "H",
      "Schedule": ""
    },
    {
      "Generic Name": "Levocetirizine",
      "Brand Names": "Xyzal, Vozet",
      "Drug Class": "Antihistamine",
      "Mechanism of Action": "Blocks H1 receptor",
      "Indications": "Allergic rhinitis",
      "Dosage & Route": "5 mg OD",
      "Absorption": "Good oral",
      "Distribution": "Low Vd",
      "Metabolism": "Minimal",
      "Elimination": "Renal",
      "Adverse Effects": "Sedation",
      "Contraindications": "CNS depressants ↑ sedation",
      "Drug Interactions": "CNS effects",
      "Monitoring Parameters": "Caution driving",
      "Patient Counseling Points": "₹5",
      "Cost (₹/tab)": "Both",
      "Availability (Govt/Private)": "OTC",
      "Schedule": ""
    },
    {
      "Generic Name": "Salbutamol",
      "Brand Names": "Asthalin, Ventolin",
      "Drug Class": "SABA",
      "Mechanism of Action": "Stimulates beta-2 → bronchodilation",
      "Indications": "Asthma",
      "Dosage & Route": "2 puffs PRN",
      "Absorption": "Lung absorption",
      "Distribution": "Wide",
      "Metabolism": "Hepatic",
      "Elimination": "Renal",
      "Adverse Effects": "Tremor, palpitations",
      "Contraindications": "Beta-blockers ↓ effect",
      "Drug Interactions": "Symptom relief",
      "Monitoring Parameters": "Use as rescue inhaler",
      "Patient Counseling Points": "₹100/inhaler",
      "Cost (₹/tab)": "Both",
      "Availability (Govt/Private)": "H",
      "Schedule": ""
    }
  ],
  "diseases": [
    {
      "Disease Name": "Dengue Fever",
      "ICD-10 Code": "A90",
      "Classification": "Viral hemorrhagic fever",
      "Etiology": "Dengue virus (DENV 1–4), transmitted via Aedes aegypti mosquito",
      "Pathogenesis": "Viral replication in macrophages → cytokine storm → capillary leak → thrombocytopenia",
      "Epidemiology (Kerala)": "Peak during monsoon (Jun–Sep); endemic in Thiruvananthapuram, Kollam",
      "Risk Factors": "Stagnant water, monsoon, poor waste management, travel history",
      "Clinical Features": "Sudden fever, myalgia, retro-orbital pain, petechiae, positive tourniquet test",
      "Diagnostic Methods": "NS1 antigen test (early), IgM/IgG ELISA, platelet count, hematocrit",
      "Differential Diagnoses": "Chikungunya, malaria, leptospirosis, typhoid",
      "Management & Treatment": "Supportive care (fluids, paracetamol); hospitalize if warning signs present",
      "First-Line Drugs": "Paracetamol for fever; avoid NSAIDs",
      "Complications": "Dengue shock syndrome, hemorrhage, hepatic failure",
      "Patient Education": "Use mosquito repellents, eliminate breeding sites, maintain hydration",
      "Govt Health Programs (Kerala)": "Kerala Dengue Control Campaign, free NS1 testing in PHCs",
      "Local Notes / Case References": "Surge in cases post-2018 floods; rapid testing kiosks set up in urban slums"
    },
    {
      "Disease Name": "Type 2 Diabetes Mellitus",
      "ICD-10 Code": "E11",
      "Classification": "Metabolic/endocrine disorder",
      "Etiology": "Insulin resistance, pancreatic β-cell dysfunction",
      "Pathogenesis": "↓ Insulin sensitivity → ↑ hepatic glucose output → hyperglycemia",
      "Epidemiology (Kerala)": "Kerala has one of the highest T2DM rates in India (~19% adults)",
      "Risk Factors": "Obesity, sedentary lifestyle, family history, age >40",
      "Clinical Features": "Polyuria, polydipsia, polyphagia, fatigue, weight loss",
      "Diagnostic Methods": "Fasting plasma glucose ≥126 mg/dL, HbA1c ≥6.5%, OGTT",
      "Differential Diagnoses": "Type 1 DM, Cushing's, MODY, medication-induced hyperglycemia",
      "Management & Treatment": "Lifestyle change + oral antidiabetics ± insulin; monitor HbA1c",
      "First-Line Drugs": "Metformin, sulfonylureas; insulin if uncontrolled",
      "Complications": "Neuropathy, nephropathy, retinopathy, cardiovascular disease",
      "Patient Education": "Regular diet, walking, glucose checks, foot care, avoid sugar",
      "Govt Health Programs (Kerala)": "NCD clinics in govt hospitals, free metformin + testing",
      "Local Notes / Case References": "Local initiatives: Kudumbashree health workers screen at-risk women in rural areas"
    },
    {
      "Disease Name": "Hypertension",
      "ICD-10 Code": "I10",
      "Classification": "Primary",
      "Etiology": "Genetic, lifestyle",
      "Pathogenesis": "↑ peripheral resistance",
      "Epidemiology (Kerala)": "~30%",
      "Risk Factors": "Age, obesity",
      "Clinical Features": "Asymptomatic, headache",
      "Diagnostic Methods": "BP, ECG",
      "Differential Diagnoses": "White coat HTN",
      "Management & Treatment": "Lifestyle + meds",
      "First-Line Drugs": "Losartan, Amlodipine",
      "Complications": "Stroke",
      "Patient Education": "Salt restriction",
      "Govt Health Programs (Kerala)": "NPCDCS",
      "Local Notes / Case References": "Urban Kerala"
    },
    {
      "Disease Name": "Asthma",
      "ICD-10 Code": "J45",
      "Classification": "Atopic",
      "Etiology": "Allergens",
      "Pathogenesis": "Airway hyperreactivity",
      "Epidemiology (Kerala)": "5-10%",
      "Risk Factors": "Family hx",
      "Clinical Features": "Wheeze",
      "Diagnostic Methods": "Spirometry",
      "Differential Diagnoses": "COPD",
      "Management & Treatment": "ICS + LABA",
      "First-Line Drugs": "Budesonide + Formoterol",
      "Complications": "Status asthmaticus",
      "Patient Education": "Trigger avoidance",
      "Govt Health Programs (Kerala)": "NPCDCS",
      "Local Notes / Case References": "Common urban"
    },
    {
      "Disease Name": "Hypothyroidism",
      "ICD-10 Code": "E03",
      "Classification": "Primary",
      "Etiology": "Autoimmune",
      "Pathogenesis": "↓ thyroid hormone",
      "Epidemiology (Kerala)": "High female prevalence",
      "Risk Factors": "Female gender",
      "Clinical Features": "Fatigue",
      "Diagnostic Methods": "TSH, T4",
      "Differential Diagnoses": "Anemia",
      "Management & Treatment": "Levothyroxine",
      "First-Line Drugs": "Levothyroxine",
      "Complications": "Myxedema",
      "Patient Education": "Adherence",
      "Govt Health Programs (Kerala)": "NPCDCS",
      "Local Notes / Case References": "Common rural"
    },
    {
      "Disease Name": "Ischemic Heart Disease",
      "ICD-10 Code": "I25",
      "Classification": "Chronic",
      "Etiology": "Atherosclerosis",
      "Pathogenesis": "Coronary artery narrowing",
      "Epidemiology (Kerala)": "High urban",
      "Risk Factors": "HTN, DM",
      "Clinical Features": "Angina",
      "Diagnostic Methods": "ECG, TMT",
      "Differential Diagnoses": "GERD",
      "Management & Treatment": "Antiplatelets, statins",
      "First-Line Drugs": "Clopidogrel, Atorvastatin",
      "Complications": "MI",
      "Patient Education": "Lifestyle mod",
      "Govt Health Programs (Kerala)": "NPCDCS",
      "Local Notes / Case References": "High mortality"
    },
    {
      "Disease Name": "COPD",
      "ICD-10 Code": "J44",
      "Classification": "Obstructive",
      "Etiology": "Smoking",
      "Pathogenesis": "Airflow limitation",
      "Epidemiology (Kerala)": "Common smokers",
      "Risk Factors": "Smoking",
      "Clinical Features": "Cough, dyspnea",
      "Diagnostic Methods": "Spirometry",
      "Differential Diagnoses": "Asthma",
      "Management & Treatment": "Bronchodilators",
      "First-Line Drugs": "Tiotropium",
      "Complications": "Cor pulmonale",
      "Patient Education": "Quit smoking",
      "Govt Health Programs (Kerala)": "NPCDCS",
      "Local Notes / Case References": "Rural elderly"
    },
    {
      "Disease Name": "Typhoid",
      "ICD-10 Code": "A01",
      "Classification": "Infectious",
      "Etiology": "Salmonella",
      "Pathogenesis": "Bacteremia",
      "Epidemiology (Kerala)": "Outbreaks",
      "Risk Factors": "Poor sanitation",
      "Clinical Features": "Fever, abd pain",
      "Diagnostic Methods": "Widal, blood culture",
      "Differential Diagnoses": "Malaria",
      "Management & Treatment": "Cefixime",
      "First-Line Drugs": "Cefixime",
      "Complications": "Intestinal perf",
      "Patient Education": "Hygiene",
      "Govt Health Programs (Kerala)": "IDSP",
      "Local Notes / Case References": "Periodic outbreaks"
    },
    {
      "Disease Name": "Rheumatoid Arthritis",
      "ICD-10 Code": "M05",
      "Classification": "Autoimmune",
      "Etiology": "Autoimmunity",
      "Pathogenesis": "Synovial inflammation",
      "Epidemiology (Kerala)": "Urban",
      "Risk Factors": "Genetic",
      "Clinical Features": "Joint pain",
      "Diagnostic Methods": "RF, anti-CCP",
      "Differential Diagnoses": "OA",
      "Management & Treatment": "DMARDs",
      "First-Line Drugs": "Methotrexate",
      "Complications": "Deformity",
      "Patient Education": "Physio",
      "Govt Health Programs (Kerala)": "-",
      "Local Notes / Case References": "Seen urban"
    },
    {
      "Disease Name": "CKD",
      "ICD-10 Code": "N18",
      "Classification": "Chronic",
      "Etiology": "DM, HTN",
      "Pathogenesis": "Nephron loss",
      "Epidemiology (Kerala)": "Rising",
      "Risk Factors": "DM",
      "Clinical Features": "Fatigue, edema",
      "Diagnostic Methods": "Creatinine",
      "Differential Diagnoses": "AKI",
      "Management & Treatment": "ACEi, dialysis",
      "First-Line Drugs": "Losartan",
      "Complications": "ESRD",
      "Patient Education": "Diet",
      "Govt Health Programs (Kerala)": "NPCDCS",
      "Local Notes / Case References": "High in DM pts"
    },
    {
      "Disease Name": "Pulmonary TB",
      "ICD-10 Code": "A15",
      "Classification": "Infectious",
      "Etiology": "Mycobacterium TB",
      "Pathogenesis": "Granulomas",
      "Epidemiology (Kerala)": "Endemic",
      "Risk Factors": "Poverty",
      "Clinical Features": "Cough, fever",
      "Diagnostic Methods": "Sputum AFB",
      "Differential Diagnoses": "Lung CA",
      "Management & Treatment": "ATT",
      "First-Line Drugs": "HRZE",
      "Complications": "Cavitation",
      "Patient Education": "Adherence",
      "Govt Health Programs (Kerala)": "RNTCP",
      "Local Notes / Case References": "Common"
    },
    {
      "Disease Name": "GERD",
      "ICD-10 Code": "K21",
      "Classification": "Functional",
      "Etiology": "LES dysfunction",
      "Pathogenesis": "Reflux",
      "Epidemiology (Kerala)": "Urban",
      "Risk Factors": "Obesity",
      "Clinical Features": "Heartburn",
      "Diagnostic Methods": "Endoscopy",
      "Differential Diagnoses": "IHD",
      "Management & Treatment": "PPI",
      "First-Line Drugs": "Rabeprazole",
      "Complications": "Stricture",
      "Patient Education": "Lifestyle",
      "Govt Health Programs (Kerala)": "-",
      "Local Notes / Case References": "Urban common"
    }
  ]
}